The European Medicines Agency EMA is starting a review of obesity drugs, reports Dagens Nyheter.
The reason is that appetite suppressant drugs such as Ozempic and Saxenda are suspected of increasing the risk of suicidal thoughts and self-injurious behavior.
150 similar reports of suspected side effects linked to the drugs have been reported to the EMA, two of which are from Sweden.
Ozempic, is a diabetes medicine, which attracted a lot of attention for its weight-reducing properties.